The company is managed by biotech professionals who succeed in global bio start-ups / public biotechs, from CMO to new drug development sectors.
We invest in companies with sciences that address unmet medical needs.
revolutionary breakthroughs in sciences.
diagnostics and personalized medicine
advances in future medicine
innovative technologies and market approachable products.
Creating Global Bio Platforms in Korea
globally network your start-up
Expose your start-up to the global market, that is potentially 47x greater than Korea’s $20 billion Market.
We handle the process of Initial funding, Late stage funding, Clinical Development, by partnering with Global Pharma/Biotechs.
With Korea’s abundance of biotech sciences and manpower, a globally networked start-up will have access to the best resouces and markets.
Bryan Byong Jin has been a leader for both public and private companies, from the start-ups to a revenue generating CMO companies in the life sciences industry.
He was a co-founder and CEO of VGX International, a KOSPI public biotech company in Korea. He started the company in 2005 by merging with a public company, Dong-Il Fabrics and initiated a new biotech unit within the company. The company became a KOSPI 200 in 2008. As a leader in DNA vaccine field, the company successfully completed the first-ever preventive DNA vaccine phase 1 clinical trials in Asia. He led series of funding in a total of $38M and structured numerous business deals including in-/out-licensing of pipelines with US and Chinese companies.
In 2008, the company acquired a DNA vaccine CMO company in Houston (and named VGXI, inc). As a new CEO, he led the restructuring and expansions of the company including building new marketing teams and strategies, the doubling of manufacturing capacity and the series of investment-in from partners. In 2010, finally the revenues were quadrupled in 2 years and achieved its first profit.
Bryan was one of starting members at VGX Pharmaceuticals. Inc. in Philadelphia, PA, a biotech start-up. He headed the corporate development as a VP and brought in Needham & Co. to complete a merge with Inovio Pharmaceuticals (AMEX: INO) in 2008. He also headed series of funding resulted in more than $20M for Phase I and II clinical trials for 4 pipelines in US, and involved with the acquisitions and spin-offs of numerous business units and pipelines for US and companies in Asia.
Prior to joining the company, he was a Clinical Associate Professor at University of Pennsylvania. He holds a Doctor of Dental Medicine from University of Pennsylvania School of Dental Medicine, a BA in Economics and a BS in Biological Sciences from University of California at Irvine.
Bryan was named Forbes Korea’s CEO of the year in 2010 and Fortunes Korea’s Best CEOs in 2011.
Calvin BG Rhee has more than 10 years experience in biomedical research and development.
Prior to joining Transcure Bio Ventures, Calvin worked at Hyundai Pharm where he assessed global biotechs in early clinical and pre-clinical development stage for license-in. Prior to that he was an R&D manager with biotech company, VGX International, where he focused on prophylactic influenza DNA vaccine and hepatitis C & B therapeutic DNA vaccine development in Asia.
Tech assessment of biologics in early stage including drug delivery systems and diagnostics.
Biologics development from animal study through to human study covering universal influenza prophylactic and hepatitis B & C therapeutic DNA vaccines.
Process development of clinical study material in GMP graded facility.
Establishment DNA vaccine collaborative research center with Seoul Asan Medical Center.
Broad experience across in-licensing, acquisitions and business development as well as fund raisings.
Hee Kwon Song is an Associate Professor of Radiologic Science in Radiology at University of Pennsylvania's School of Medicine.
Hee Kwon has been active in biomedical research for more than 20 years. With background in both electrical and bio-engineering, he currently carries out research in developing novel magnetic resonance imaging (MRI) strategies for tumor assessment at Penn.
The research Hee Kwon and his colleagues at Penn have carried out have also led to MicroMRI, Inc., a medical device start-up focused on developing and commercializing novel and innovative hardware and software products that perform high resolution MRI of bone micro-architecture.
Throughout his research career in academia, Hee Kwon has been successful in the procurement of funding from various institutions and foundations, including the National Institutes of Health (NIH), the National Science Foundation (NSF), American Cancer Society, and the Department of Defense.
you can use the contact form below to contact us directly.